ReviewTranslational neurodegeneration2017
Mild cognitive impairment in Parkinson's disease: a distinct clinical entity?
Review in Translational neurodegeneration, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- A qualitative approach to extract diagnostic patterns of cognitive impairment in Parkinson's disease.Scientific reports · 2026Article
- Recommendations to Improve Healthcare Service Provision for Cognitive Impairment in People With Parkinson's Disease: A Mixed Methods Study of the Lived Experience Expert Perspective.Health expectations : an international journal of public participation in health care and health policy · 2026Article
- Data-driven clinical decision support tool for diagnosing mild cognitive impairment in Parkinson's disease.NPJ Parkinson's disease · 2026Article
- Predictive value of cerebrospinal fluid Alzheimer's disease biomarkers and neuropsychological measures for cognitive and motor outcomes in Parkinson's disease.Brain communications · 2026Article
- A Qualitative Approach to Extract Diagnostic Patterns of Cognitive Impairment in Parkinson's Disease.Research square · 2025Article
- Association Between Socioeconomic Status and Neuropsychiatric Symptoms in the UK Biobank: The Moderating Role of Sociability.Depression and anxiety · 2025Article
- Review
- Mild cognitive impairment in Huntington's disease: challenges and outlooks.Journal of neural transmission (Vienna, Austria : 1996) · 2024Review
- CSF neurochemical profile and cognitive changes in Parkinson's disease with mild cognitive impairment.NPJ Parkinson's disease · 2023Article
- Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.Cerebral cortex (New York, N.Y. : 1991) · 2022Article
- Cognitive Reserve, Executive Function, and Memory in Parkinson's Disease.Brain sciences · 2021Article
- Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.Current neuropharmacology · 2021Review
- Mild Cognitive Impairment inFrontiers in psychology · 2021Article
- Beyond PD-MCI: objectively defined subtle cognitive decline predicts future cognitive and functional changes.Journal of neurology · 2021Article
- Mild Cognitive Impairment as an Early Landmark in Huntington's Disease.Frontiers in neurology · 2021Article
- Neuronal changes and cognitive deficits in a multi-hit rat model following cumulative impact of early life stressors.Biology open · 2020Article
- Parkinson's Disease-Cognitive Rating Scale for Evaluating Cognitive Impairment in Parkinson's Disease: A Systematic Review.Brain sciences · 2020Review
- Validation of Revised Chinese Version of PD-CRS in Parkinson's Disease Patients.Parkinson's disease · 2020Article
- Effect of Rapid Eye Movement Sleep Behavior Disorder on Obstructive Sleep Apnea Severity and Cognition of Parkinson's Disease Patients.Chinese medical journal · 2018Article
- Evaluation of RNA Blood Biomarkers in the Parkinson's Disease Biomarkers Program.Frontiers in aging neuroscience · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMild cognitive impairment in Parkinson's disease (PD-MCI) is a common clinical condition. Understanding its pathology and clinical features is important for early intervention before the onset of dementia. In the past, variable definitions and differences in neuropsychological batteries generated divergent results of the affected cognitive patterns. MAIN BODY: The introduction of PD-MCI criteria by the Movement Disorders Society (MDS) Task Force provides a more uniform system for defining and measuring PD-MCI and may improve the validity of future research. PD-MCI is likely to be heterogeneous since it can coexist with Alzheimer's disease and/ or Lewy body pathologies in PD. Pathogeneses of neuropsychiatric disturbances, such as depression, anxiety and apathy, are associated with PD with or without MCI. In addition, cognitive reserve formed by patients' unique life experiences may influence the outward cognitive performance despite the presence of the aforementioned pathogeneses and hence alter the diagnosis of MCI.
conclusionThe overlap of cognitive impairment across different neurodegenerative diseases suggests that PD-MCI is likely to result from a mixture of complex pathophysiologies, rather than being a distinct pathologic entity. Differentiating MCI from other organic symptoms in PD would facilitate novel therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.